Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy Versus Intensity-Modulated Proton Therapy for Localized Prostate Cancer
Open Access
- 2 April 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (4) , 212
Abstract
Purpose: This study aimed to compare long-term patient-reported outcomes in bowel and urinary domains between intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) for localized prostate cancer. Methods and Materials: Patients with clinical T1–T2 prostate cancer receiving IMRT or IMPT at a tertiary cancer center from 2015–2018 were analyzed to determine the changes in the prospectively collected bowel function (BF), urinary irritative/obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26. The mean changes in EPIC-26 scores were evaluated from pretreatment to 24 months post-radiotherapy for each modality. A score change >50% of the baseline standard deviation was considered a clinically meaningful change. Results: A total of 82 patients treated with IMRT (52.2%) and 56 patients treated with IMPT (53.3%) completed the questionnaire at baseline and 24 months post-RT. There were no baseline differences in domain scores between treatment modalities. At 24 months post-radiotherapy, there was a significant and clinically meaningful decline in the BF mean score in the IMRT cohort (−4.52 (range −50, 29.17), p = 0.003), whereas the decline in BF score did not reach clinical relevance or significance (−1.88 (range −37.5, 50), p = 0.046) when accounting for the Bonferroni adjustment in the IMPT cohort. A higher proportion of patients treated with IMRT had a clinically relevant reduction in BF when compared with IMPT (47.37% vs. 25.93%, p = 0.017). The mean changes in the UI and UO scores of the IMRT and IMPT cohorts were neither statically significant nor clinically relevant. Conclusions: IMPT leads to a smaller decrease in BF than IMRT at 24 months post-RT, while there was no differential effect on UO and UI.Keywords
This publication has 22 references indexed in Scilit:
- Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Comparing bowel and urinary domains of patient‐reported quality of life at the end of and 3 months post radiotherapy between intensity‐modulated radiotherapy and proton beam therapy for clinically localized prostate cancerCancer Medicine, 2020
- IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric ComparisonInternational Journal of Particle Therapy, 2019
- Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional RadiotherapyJAMA Oncology, 2019
- Long‐term outcomes in patients treated with proton therapy for localized prostate cancerCancer Medicine, 2017
- Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancerCancer, 2013
- Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancerCancer, 2013
- Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate CancerJAMA, 2012
- Outcomes After Intensity-Modulated Versus Conformal Radiotherapy in Older Men With Nonmetastatic Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Late Gastrointestinal Toxicities Following Radiation Therapy for Prostate CancerEuropean Urology, 2011